1259332-94-9

Basic information

• Product Name: 1-(4-fluorophenyl)-4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine
• CAS NO: 1259332-94-9
• Molecular Weight: 369.319
• Mol File: 1259332-94-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(4-fluorophenyl)-4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorophenyl)-4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine(1259332-94-9)
• EPA Substance Registry System: 1-(4-fluorophenyl)-4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine(1259332-94-9)

Safety Data

• Hazardous Substances Data: 1259332-94-9(Hazardous Substances Data)

Upstream product

• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 

Relevant articles and documents

Arylpiperazines for management of benign prostatic hyperplasia: Design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies

A series of 27 aryl/heteroaryl/aralkyl/aroyl piperazines were synthesized, and most of these compounds reduced prostate weight of mature rats by 15-47%. Three compounds, 10, 12, and 18, had better activity profile (reduced prostate weight by 47%, 43%, and 39%, respectively) than the standard drug flutamide (24% reduction). QSAR suggested structures with more cyclic and branched moieties, increased topological separation of O and N therein, and reduced solvation connectivity index for better activity. Pharmacokinetic study with compound 10 at an oral dose of 10.0 mg/kg indicated good absorption, negligible extrahepatic elimination, and rapid distribution to the target organ (prostate) but restricted entry through the blood-brain barrier. A 10-fold decrease in PSA and 15-fold increase in ER-β gene expressions of human prostate cancer cells (LNCaP) by compound 10 in vitro indicated AR and ER-β mediated actions. The findings may stimulate further explorations of identified lead for the management of benign prostatic hyperplasia.